Intranasal gene therapy to prevent infection by SARS-CoV-2 variantsJoshua J. Sims, James M. Wilson|PLoS Pathogens|2021Cited by 48
High activity of an affinity-matured ACE2 decoy against Omicron SARS-CoV-2 and pre-emergent coronavirusesJoshua J. Sims, James M. Wilson|PLoS ONE|2022Cited by 9
Intranasal gene therapy to prevent infection by SARS-CoV-2 variantsJoshua J. Sims, James M. Wilson|bioRxiv (Cold Spring Harbor Laboratory)|2021Cited by 6
High activity of an affinity-matured ACE2 decoy against Omicron SARS-CoV-2 and pre-emergent coronavirusesJoshua J. Sims, James M. Wilson|bioRxiv (Cold Spring Harbor Laboratory)|2022Cited by 1